Navigation Links
BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
Date:11/30/2011

NOVATO, Calif., Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia for an upfront payment of $81 million.  The intellectual property includes patents related to the purified form of Naglazyme and the method of using the enzyme in the treatment of MPS VI, which expire between 2022 and 2023.  Prior to this transaction, BioMarin licensed this intellectual property from SA Pathology and paid a five percent royalty on net sales of Naglazyme. 

"We are pleased to complete this transaction as we are confident in the future sales potential of Naglazyme.  We continue to expand the product into new geographies and expect steady growth for years to come.  We do not see any competition on the horizon due to the extremely small patient population, the complexity and expense of manufacturing the product and the intellectual property covered by the patents," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "The transaction will allow BioMarin to generate approximately $10 to $15 million in cash per year with no incremental operating costs.  This deal makes sense for BioMarin because we see continued growth in the global Naglazyme business."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme; the financial performance of the BioMarin as a whole; the continued clinical development and commercialization of Naglazyme; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for Naglazyme; actual sales of Naglazyme; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:

 Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570 

(415) 506-3267 


'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
2. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
3. BioMarin to Host a Research and Development Day on December 8th
4. BioMarin Announces Third Quarter 2011 Financial Results
5. BioMarin to Present at the UBS Global Life Sciences Conference
6. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
7. BioMarin to Present at the Baird Health Care Conference
8. BioMarin to Present at the Wedbush Life Sciences Conference
9. BioMarin Announces Second Quarter 2011 Financial Results
10. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
11. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Governor Andrew M. Cuomo today announced a major ... Western New York . This announcement, ... Institute, includes a major expansion of Athenex,s North American ... , as well as the creation of a ... Dunkirk . The combined projects are expected to ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... 2016  AfterPill.com is reporting that this week,s Centers ... all women who are at risk of unintended pregnancy ... and raises the risks of unprotected sex in particular.  ... According to the Guttmacher Institute, there are 43 million ... age, who have sex without the intention of becoming ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... ... 11, 2016 , ... AccuVein Inc. announces the Infusion Nurses ... Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ), ... market, facilitates adherence to this standard with its easy to use, widely deployed ...
(Date:2/11/2016)... ... , ... The annual list showcases the 20 Most Promising SharePoint Solution Providers ... and commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s ... recognize and promote technology entrepreneurship. , The survey was made at the end ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan Scientific, LLC, ... used in physical therapy, occupational therapy and sports medicine clinics, hospitals, universities and ... and therapy, introduces its new microFET Digital Pinch Gauge. , Hoggan Scientific ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led ... rates of several common cancer screenings, especially among women. Cancer screenings are often ... rates. , The study,“What Does Medicaid Expansion Mean for Cancer Screening and ...
Breaking Medicine News(10 mins):